Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Major depressive disorder (DSM-IV)~2. Depression of moderate to severe degree (17+ on the 17-item Hamilton Depression Scale (HAM-D)).~3. No Magnetic Resonance Imaging (MRI) contraindications~4. No SSRI contraindications~5. Has a general practitioner (GP) or other mental healthcare professional who can confirm diagnosis~6. 18-80 years of age~7. Males and females~8. Sufficiently competent with English language~Key exclusion criteria:~1. Current or previously diagnosed psychotic disorder~2. Immediate family member with a diagnosed psychotic disorder~3. Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure e.g. creatine clearance:renal clearance (CLRC) \< 30 ml/min etc.)~4. History of serious suicide attempts requiring hospitalisation.~5. Significant history of mania (determined by study psychiatrist and medical records)~6. Psychiatric condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin, e.g. borderline personality disorder~7. Blood or needle phobia~8. Positive pregnancy test at screening or during the study, women who are planning a pregnancy and/or women who are nursing/breastfeeding.~9. Participants who do not agree to use an acceptable contraceptive method throughout their participation in study.~10. Current drug or alcohol dependence~11. No email access~12. Use of contraindicated medication~13. Patients presenting with abnormal QT interval prolongation at screening or with a history of this (QTc at screening above 440ms for men and above 470ms for women)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Patients receive Psilocybin
- Escitalopram (Type: ACTIVE_COMPARATOR): Patients receive Escitalopram

Based on this trial design, predict the completion outcome and termination type (if applicable).